Does serum 1,5-anhydroglucitol establish a relationship between improvements in HbA1c and postprandial glucose excursions? Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine

A. C. Moses, Philip Raskin, N. Khutoryansky

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Aim: To investigate the relationship between changes in glycated haemoglobin (HbA1c) and postprandial glucose excursions on 1,5-anhydroglucitol (1,5-AG) in patients with Type 2 diabetes, utilizing the differential effects between biphasic insulin aspart 30 (BIAsp 30) or insulin glargine (IGlar) on postprandial glucose (PPG) levels. Methods: 1,5-AG was measured using the GlycoMark® assay at baseline and after 12 and 28 weeks in the INITiation of Insulin to reach HbA1c Target (INITIATE) study of 233 patients randomized to either BIAsp 30 or IGlar. Results: Baseline 1,5-AG was low and not significantly different (4.9 ± 3.5 and 4.3 ± 2.6 μg/ml in the BIAsp 30 and IGlar groups, respectively). After 28 weeks, the levels of 1,5-AG were higher in the BIAsp 30 than in the IGlar group (13.4 vs. 11.1 μg/ml, P = 0.008) and change from baseline was 25% greater with BIAsp 30 than IGlar (8.4 vs. 6.7 μg/ml, P = 0.011). 1,5-AG levels increased as a function of decreasing HbA1c or the average change in postprandial plasma glucose (PPGave) with significant relationships for 1,5-AG/ HbA1c vs. HbA1c or 1,5-AG/PPGavevs. PPG ave (both P < 0.0001), respectively. Conclusions: As reported in previous publications, 1,5-AG reflects ambient glycaemic control and increases with reductions in HbA1c and postprandial glucose. The greater reductions in postprandial excursion achieved with BiAsp 30 compared with glargine were associated with greater increases in 1,5-AG. Even moderate elevations in HbA1c substantially lower 1,5-AG, suggesting that it can be most discriminating in identifying patients with excessive postprandial glucose excursions at HbA1c levels that approach the upper end of the normal range.

Original languageEnglish (US)
Pages (from-to)200-205
Number of pages6
JournalDiabetic Medicine
Volume25
Issue number2
DOIs
StatePublished - Feb 2008

Fingerprint

Glucose
Serum
insulin aspart, insulin aspart protamine drug combination 30:70
Insulin Glargine
1,5-anhydroglucitol
Glycosylated Hemoglobin A
Type 2 Diabetes Mellitus
Birds
Reference Values
Insulin

Keywords

  • Basal
  • Glycaemic control
  • Insulin analogues
  • Target
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

@article{bbbbb77461b547c9933be10b90db82d8,
title = "Does serum 1,5-anhydroglucitol establish a relationship between improvements in HbA1c and postprandial glucose excursions? Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine",
abstract = "Aim: To investigate the relationship between changes in glycated haemoglobin (HbA1c) and postprandial glucose excursions on 1,5-anhydroglucitol (1,5-AG) in patients with Type 2 diabetes, utilizing the differential effects between biphasic insulin aspart 30 (BIAsp 30) or insulin glargine (IGlar) on postprandial glucose (PPG) levels. Methods: 1,5-AG was measured using the GlycoMark{\circledR} assay at baseline and after 12 and 28 weeks in the INITiation of Insulin to reach HbA1c Target (INITIATE) study of 233 patients randomized to either BIAsp 30 or IGlar. Results: Baseline 1,5-AG was low and not significantly different (4.9 ± 3.5 and 4.3 ± 2.6 μg/ml in the BIAsp 30 and IGlar groups, respectively). After 28 weeks, the levels of 1,5-AG were higher in the BIAsp 30 than in the IGlar group (13.4 vs. 11.1 μg/ml, P = 0.008) and change from baseline was 25{\%} greater with BIAsp 30 than IGlar (8.4 vs. 6.7 μg/ml, P = 0.011). 1,5-AG levels increased as a function of decreasing HbA1c or the average change in postprandial plasma glucose (PPGave) with significant relationships for 1,5-AG/ HbA1c vs. HbA1c or 1,5-AG/PPGavevs. PPG ave (both P < 0.0001), respectively. Conclusions: As reported in previous publications, 1,5-AG reflects ambient glycaemic control and increases with reductions in HbA1c and postprandial glucose. The greater reductions in postprandial excursion achieved with BiAsp 30 compared with glargine were associated with greater increases in 1,5-AG. Even moderate elevations in HbA1c substantially lower 1,5-AG, suggesting that it can be most discriminating in identifying patients with excessive postprandial glucose excursions at HbA1c levels that approach the upper end of the normal range.",
keywords = "Basal, Glycaemic control, Insulin analogues, Target, Type 2 diabetes",
author = "Moses, {A. C.} and Philip Raskin and N. Khutoryansky",
year = "2008",
month = "2",
doi = "10.1111/j.1464-5491.2008.02384.x",
language = "English (US)",
volume = "25",
pages = "200--205",
journal = "Diabetic Medicine",
issn = "0742-3071",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Does serum 1,5-anhydroglucitol establish a relationship between improvements in HbA1c and postprandial glucose excursions? Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine

AU - Moses, A. C.

AU - Raskin, Philip

AU - Khutoryansky, N.

PY - 2008/2

Y1 - 2008/2

N2 - Aim: To investigate the relationship between changes in glycated haemoglobin (HbA1c) and postprandial glucose excursions on 1,5-anhydroglucitol (1,5-AG) in patients with Type 2 diabetes, utilizing the differential effects between biphasic insulin aspart 30 (BIAsp 30) or insulin glargine (IGlar) on postprandial glucose (PPG) levels. Methods: 1,5-AG was measured using the GlycoMark® assay at baseline and after 12 and 28 weeks in the INITiation of Insulin to reach HbA1c Target (INITIATE) study of 233 patients randomized to either BIAsp 30 or IGlar. Results: Baseline 1,5-AG was low and not significantly different (4.9 ± 3.5 and 4.3 ± 2.6 μg/ml in the BIAsp 30 and IGlar groups, respectively). After 28 weeks, the levels of 1,5-AG were higher in the BIAsp 30 than in the IGlar group (13.4 vs. 11.1 μg/ml, P = 0.008) and change from baseline was 25% greater with BIAsp 30 than IGlar (8.4 vs. 6.7 μg/ml, P = 0.011). 1,5-AG levels increased as a function of decreasing HbA1c or the average change in postprandial plasma glucose (PPGave) with significant relationships for 1,5-AG/ HbA1c vs. HbA1c or 1,5-AG/PPGavevs. PPG ave (both P < 0.0001), respectively. Conclusions: As reported in previous publications, 1,5-AG reflects ambient glycaemic control and increases with reductions in HbA1c and postprandial glucose. The greater reductions in postprandial excursion achieved with BiAsp 30 compared with glargine were associated with greater increases in 1,5-AG. Even moderate elevations in HbA1c substantially lower 1,5-AG, suggesting that it can be most discriminating in identifying patients with excessive postprandial glucose excursions at HbA1c levels that approach the upper end of the normal range.

AB - Aim: To investigate the relationship between changes in glycated haemoglobin (HbA1c) and postprandial glucose excursions on 1,5-anhydroglucitol (1,5-AG) in patients with Type 2 diabetes, utilizing the differential effects between biphasic insulin aspart 30 (BIAsp 30) or insulin glargine (IGlar) on postprandial glucose (PPG) levels. Methods: 1,5-AG was measured using the GlycoMark® assay at baseline and after 12 and 28 weeks in the INITiation of Insulin to reach HbA1c Target (INITIATE) study of 233 patients randomized to either BIAsp 30 or IGlar. Results: Baseline 1,5-AG was low and not significantly different (4.9 ± 3.5 and 4.3 ± 2.6 μg/ml in the BIAsp 30 and IGlar groups, respectively). After 28 weeks, the levels of 1,5-AG were higher in the BIAsp 30 than in the IGlar group (13.4 vs. 11.1 μg/ml, P = 0.008) and change from baseline was 25% greater with BIAsp 30 than IGlar (8.4 vs. 6.7 μg/ml, P = 0.011). 1,5-AG levels increased as a function of decreasing HbA1c or the average change in postprandial plasma glucose (PPGave) with significant relationships for 1,5-AG/ HbA1c vs. HbA1c or 1,5-AG/PPGavevs. PPG ave (both P < 0.0001), respectively. Conclusions: As reported in previous publications, 1,5-AG reflects ambient glycaemic control and increases with reductions in HbA1c and postprandial glucose. The greater reductions in postprandial excursion achieved with BiAsp 30 compared with glargine were associated with greater increases in 1,5-AG. Even moderate elevations in HbA1c substantially lower 1,5-AG, suggesting that it can be most discriminating in identifying patients with excessive postprandial glucose excursions at HbA1c levels that approach the upper end of the normal range.

KW - Basal

KW - Glycaemic control

KW - Insulin analogues

KW - Target

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=39749118072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39749118072&partnerID=8YFLogxK

U2 - 10.1111/j.1464-5491.2008.02384.x

DO - 10.1111/j.1464-5491.2008.02384.x

M3 - Article

C2 - 18290862

AN - SCOPUS:39749118072

VL - 25

SP - 200

EP - 205

JO - Diabetic Medicine

JF - Diabetic Medicine

SN - 0742-3071

IS - 2

ER -